rs1059394
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_017512.7(ENOSF1):c.*1513G>A variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.34 in 1,475,262 control chromosomes in the GnomAD database, including 91,444 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.40 ( 13109 hom., cov: 32)
Exomes 𝑓: 0.33 ( 78335 hom. )
Consequence
ENOSF1
NM_017512.7 3_prime_UTR
NM_017512.7 3_prime_UTR
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 0.0720
Publications
23 publications found
Genes affected
ENOSF1 (HGNC:30365): (enolase superfamily member 1) This gene can encode a mitochondrial enzyme that is thought to convert L-fuconate to 2-keto-3-deoxy-L-fuconate. This locus was originally identified as the source of antisense RNAs of the adjacent thymidylate synthase gene. Splice variants at this locus may contain an alternate 3' exon that is complementary to the 3'UTR and terminal intron of the thymidylate synthase (TS) RNA and may downregulate TS expression. [provided by RefSeq, Aug 2017]
TYMS (HGNC:12441): (thymidylate synthetase) Thymidylate synthase catalyzes the methylation of deoxyuridylate to deoxythymidylate using, 10-methylenetetrahydrofolate (methylene-THF) as a cofactor. This function maintains the dTMP (thymidine-5-prime monophosphate) pool critical for DNA replication and repair. The enzyme has been of interest as a target for cancer chemotherapeutic agents. It is considered to be the primary site of action for 5-fluorouracil, 5-fluoro-2-prime-deoxyuridine, and some folate analogs. Expression of this gene and that of a naturally occurring antisense transcript, mitochondrial enolase superfamily member 1 (GeneID:55556), vary inversely when cell-growth progresses from late-log to plateau phase. Polymorphisms in this gene may be associated with etiology of neoplasia, including breast cancer, and response to chemotherapy. [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.89).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.665 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.398 AC: 60390AN: 151896Hom.: 13094 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
60390
AN:
151896
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.334 AC: 441775AN: 1323248Hom.: 78335 Cov.: 21 AF XY: 0.337 AC XY: 218461AN XY: 648498 show subpopulations
GnomAD4 exome
AF:
AC:
441775
AN:
1323248
Hom.:
Cov.:
21
AF XY:
AC XY:
218461
AN XY:
648498
show subpopulations
African (AFR)
AF:
AC:
17203
AN:
30544
American (AMR)
AF:
AC:
11662
AN:
36538
Ashkenazi Jewish (ASJ)
AF:
AC:
8103
AN:
21242
East Asian (EAS)
AF:
AC:
25621
AN:
38314
South Asian (SAS)
AF:
AC:
28779
AN:
65652
European-Finnish (FIN)
AF:
AC:
14708
AN:
49044
Middle Eastern (MID)
AF:
AC:
2515
AN:
5150
European-Non Finnish (NFE)
AF:
AC:
313368
AN:
1022802
Other (OTH)
AF:
AC:
19816
AN:
53962
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.508
Heterozygous variant carriers
0
13657
27313
40970
54626
68283
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
11260
22520
33780
45040
56300
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.398 AC: 60437AN: 152014Hom.: 13109 Cov.: 32 AF XY: 0.402 AC XY: 29840AN XY: 74306 show subpopulations
GnomAD4 genome
AF:
AC:
60437
AN:
152014
Hom.:
Cov.:
32
AF XY:
AC XY:
29840
AN XY:
74306
show subpopulations
African (AFR)
AF:
AC:
22872
AN:
41432
American (AMR)
AF:
AC:
5123
AN:
15278
Ashkenazi Jewish (ASJ)
AF:
AC:
1365
AN:
3472
East Asian (EAS)
AF:
AC:
3539
AN:
5172
South Asian (SAS)
AF:
AC:
2144
AN:
4804
European-Finnish (FIN)
AF:
AC:
3221
AN:
10558
Middle Eastern (MID)
AF:
AC:
138
AN:
292
European-Non Finnish (NFE)
AF:
AC:
21035
AN:
67984
Other (OTH)
AF:
AC:
848
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1787
3574
5361
7148
8935
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
570
1140
1710
2280
2850
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2003
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.